Company intelligence / Profile preview

Vasculonics

Indianapolis, Indiana, United Statesvasculonics.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Developing disease-modifying therapies for pulmonary arterial hypertension and other conditions. Currently in preclinical stage with grant validation including a Catalyze grant and an SBIR phase 2a for $2.1M starting at the end of 2024

Therapeutic areas
NephrologyOtherCardiovascularNeurologyInfectious Diseases
Modalities
Small molecules (oral tablet VN-1032)Medical device (extracorporeal device VN-901)
Industry
Biotech
02

Drug pipeline

2 assets

VN-1032

Preclinical

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Vasculonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vasculonics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call